

ASTHMA & ALLERGY REFERRAL FORM (A-F)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION					
Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN	Primary Language
Address		City	State	ZIP	
Email	Home Phone	Work Phone	Cell Phone		
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT					
Primary Caregiver/Alt Contact Name (If applicable)			Alt Contact Email		Alt Contact Phone

PRESCRIBER INFORMATION					
Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax		
Referral Contact Email		Office Phone	Office Fax		
Practice / Facility Name		Prescriber Name / Specialty			
Address		City	State	ZIP	
Prescriber State License #	DEA #	NPI #	Medicaid UPIN #		

** Please include a copy of the front and back of insurance card **

CLINICAL INFORMATION - Please include applicable clinical chart notes					
Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>					Therapy Start Date
Therapies Tried and Failed (please list medications)					
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:	
If Self-injectable drug, is injection training coordination required by our pharmacy? <input type="checkbox"/> Yes <input type="checkbox"/> No			Patient has had Chronic Idiopathic Urticaria for 6 weeks or more <input type="checkbox"/> Yes <input type="checkbox"/> No		
Other/Concomitant Medications (please list)					
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)					
Allergic Asthma		Pretreatment serum IgE level _____ IU/mL		Test date _____	
<input type="checkbox"/> History of positive skin or RAST test to a perennial aeroallergen		Pretreatment FEV1 (if available) _____ %		Date obtained _____	
<input type="checkbox"/> Symptoms inadequately controlled with ICS		Eosinophil levels (if available) _____ cells/mcL		Test date _____	
		Number of severe exacerbations in the past 12 months _____			
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)					
ICD-10 Code <input type="checkbox"/> Code _____		Description _____		<input type="checkbox"/> Code _____ Description _____	
<input type="checkbox"/> Date of Diagnosis _____					

PRESCRIPTION INFORMATION - Please Escribe if required by state law
In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Cinqair	<input type="checkbox"/> 10 mg/ml	<input type="checkbox"/> 3mg/kg IV infusion over 20 to 50 minutes every 4 weeks		
<input type="checkbox"/> Dupixent	PFS <input type="checkbox"/> 100 mg/0.67 ml PFS <input type="checkbox"/> 200 mg/1.14 ml PFS <input type="checkbox"/> 300 mg/2ml PFS PEN <input type="checkbox"/> 200 mg/1.14 ml pre-filled pen* <input type="checkbox"/> 300 mg/2 ml pre-filled pen* *comes in cartons of 2	Pediatric 15 to <30kg: <input type="checkbox"/> Inject 100 mg SC (one injection) every other week <input type="checkbox"/> Inject 300 mg SC (one injection) every four weeks Pediatric ≥30 kg: <input type="checkbox"/> Inject 200 mg SC (one injection) every other week Adult Initial Dose: <input type="checkbox"/> Inject 400 mg SC (2-200 mg injections in different injection sites) initially then 200 mg SC every other week <input type="checkbox"/> Inject 600 mg SC (2-300 mg injections in different injection sites) initially then 300 mg SC every other week Adult Maintenance Dose: <input type="checkbox"/> Inject 200 mg (one injection) SC every other week <input type="checkbox"/> Inject 300 mg (one injection) SC every other week Chronic Sinusitis with Nasal Polyposis: <input type="checkbox"/> Inject 300 mg (one injection) SC every other week Other: <input type="checkbox"/> _____		
<input type="checkbox"/> Fasenra	<input type="checkbox"/> 30 mg/ml Auto-Injector <input type="checkbox"/> 30 mg/ml PFS	Adults and Pediatrics (age 12 or greater) - 30mg subcutaneously once every 4 weeks for the first 3 doses, and then once every 8 weeks		

_____ Prescriber Signature	_____ Date	_____ Supervising Physician Signature (where required by state law)	_____ Date
_____ DAW (Dispense as Written)	_____ Date	_____ Brand Necessary (must handwrite)	

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

ASTHMA & ALLERGY REFERRAL FORM (G-Z)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION					
Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN	Primary Language
Address		City	State		ZIP
Email	Home Phone	Work Phone		Cell Phone	
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT					
Primary Caregiver/Alt Contact Name (If applicable)			Alt Contact Email		Alt Contact Phone

PRESCRIBER INFORMATION					
Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax		
Referral Contact Email		Office Phone	Office Fax		
Practice / Facility Name		Prescriber Name / Specialty			
Address		City	State	ZIP	
Prescriber State License #	DEA #	NPI #	Medicaid UPIN #		

*** Please include a copy of the front and back of insurance card ***

CLINICAL INFORMATION - Please include applicable clinical chart notes					
Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>					Therapy Start Date
Therapies Tried and Failed (please list medications)					
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:	
If Self-injectable drug, is injection training coordination required by our pharmacy? <input type="checkbox"/> Yes <input type="checkbox"/> No			Patient has had Chronic Idiopathic Urticaria for 6 weeks or more <input type="checkbox"/> Yes <input type="checkbox"/> No		
Other/Concomitant Medications (please list)					
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)					
Allergic Asthma		Pretreatment serum IgE level _____ IU/mL	Test date _____		
<input type="checkbox"/> History of positive skin or RAST test to a perennial aeroallergen		Pretreatment FEV1 (if available) _____ %	Date obtained _____		
<input type="checkbox"/> Symptoms inadequately controlled with ICS		Eosinophil levels (if available) _____ cells/mcL	Test date _____		
		Number of severe exacerbations in the past 12 months _____			
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)					
ICD-10 Code <input type="checkbox"/> Code _____ Description _____		<input type="checkbox"/> Code _____ Description _____			
<input type="checkbox"/> Date of Diagnosis _____					

PRESCRIPTION INFORMATION - Please Escribe if required by state law
In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.

MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Xolair Every FOUR weeks dosing. (dose dependent on weight and IgE levels)	VIAL <input type="checkbox"/> 150 mg vial kit PFS <input type="checkbox"/> 75 mg/0.5 ml <input type="checkbox"/> 150 mg/0.5 ml <input type="checkbox"/> To be administered by a Healthcare Professional <input type="checkbox"/> Shipping to Home: Has patient received at least 3 doses of Xolair under the guidance of a healthcare provider with no hypersensitivity reaction? <input type="checkbox"/> Yes <input type="checkbox"/> No	Every 4 weeks dosing: <input type="checkbox"/> Administer 75 mg per dose subcutaneously every 4 weeks <input type="checkbox"/> Administer 150 mg per dose subcutaneously every 4 weeks <input type="checkbox"/> Administer 225 mg per dose subcutaneously every 4 weeks <input type="checkbox"/> Administer 300 mg per dose subcutaneously every 4 weeks <input type="checkbox"/> Other: Administer _____ mg per dose subcutaneously every 4 weeks Every 2 weeks dosing: <input type="checkbox"/> Administer 225 mg per dose subcutaneously every 2 weeks <input type="checkbox"/> Administer 300 mg per dose subcutaneously every 2 weeks <input type="checkbox"/> Administer 375 mg per dose subcutaneously every 2 weeks <input type="checkbox"/> Other: Administer _____ mg per dose subcutaneously every 2 weeks		
<input type="checkbox"/> EpiPen		<input type="checkbox"/> Use as directed		
<input type="checkbox"/> EpiPen Jr.		<input type="checkbox"/> Use as directed		

_____ Prescriber Signature	_____ Date	_____ Supervising Physician Signature (where required by state law)	_____ Date
_____ DAW (Dispense as Written)	_____ Date	_____ Brand Necessary (must handwrite)	

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.